XML 39 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Variable Interest Entities (Tables)
6 Months Ended
Jun. 30, 2016
Variable Interest Entity Disclosure [Abstract]  
Summary of Investments in Unconsolidated Variable Interest Entities and Estimated Maximum Exposure to Loss

As of June 30, 2016, the Company’s investments in unconsolidated variable interest entities (“VIEs”) and its estimated maximum exposure to loss were as follows (in thousands):

 

 

 

Investments in Unconsolidated VIEs

 

 

Maximum Exposure to Loss

 

NovaQuest Pharma Opportunities Fund III, L.P.

 

$

40,077

 

 

$

48,612

 

NovaQuest Pharma Opportunities Fund IV, L.P.

 

 

6,850

 

 

 

19,775

 

 

 

$

46,927

 

 

$

68,387